Company intelligence / Profile preview

Avizorex Pharma

Barcelona (Barcelona Science Park office)[6], Catalonia/Comunitat Valenciana, Spainmarketscreener.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Avizorex’s lead candidate, AVX‑012, demonstrated positive results in a Phase 2a clinical trial for dry eye disease. The drug acts as a potent and selective TRPM8 agonist to physiologically stimulate tear film stability and reduce discomfort. A larger Phase 2b study was planned following the acquisition by Aerie Pharmaceuticals[1][4][6].

Therapeutic areas: Ophthalmology
Modalities: Small molecules (notably TRPM8 agonists)
Industry: Biotech

Drug pipeline

1 asset

AVX-012

Phase 2

Indications: Dry eye disease

Partnerships

Acquired by Aerie Pharmaceuticalspreviously backed by Inveready VC fund[7]

Beyond the preview

Go deeper on Avizorex Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avizorex Pharma.

Explore the full profile